LG AI Research, part of the South Korean LG Group, has announced the release of its updated artificial intelligence model EXAONE Path 2.0 for pathology research.

This was reported by Yonhap.

The laboratory revealed that compared to the previous version 1.0, EXAONE Path 2.0 offers significantly enhanced accuracy in analyzing and predicting genetic mutations, gene expression patterns, and minor structural changes in human cells and tissues using pathological tissue images.

It was noted that the model has been trained on over 10,000 datasets, including visualization and multi-omics, enabling it to predict gene activity solely based on image analysis without the need for costly genomic testing.

«With EXAONE Path 2.0, genetic testing can be completed in less than a minute, compared to more than two weeks previously required. This will help save crucial time for treating cancer patients,» said lead researcher at LG AI Research, Park Yong-min.

He added that doctors and pharmaceutical companies can utilize EXAONE Path 2.0 for rapid analysis of pathological images from cancer patients, detecting gene mutations and selecting appropriate targeted therapies.

As reported earlier, the Chinese company DeepSeek has unveiled its updated artificial intelligence model DeepSeek R1, thus enhancing its competition with OpenAI, the developer of the popular chatbot ChatGPT.